These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 32708525)

  • 41. Publisher Correction: SARS-CoV-2 disrupts host epigenetic regulation via histone mimicry.
    Kee J; Thudium S; Renner DM; Glastad K; Palozola K; Zhang Z; Li Y; Lan Y; Cesare J; Poleshko A; Kiseleva AA; Truitt R; Cardenas-Diaz FL; Zhang X; Xie X; Kotton DN; Alysandratos KD; Epstein JA; Shi PY; Yang W; Morrisey E; Garcia BA; Berger SL; Weiss SR; Korb E
    Nature; 2023 Jan; 613(7945):E5. PubMed ID: 36624294
    [No Abstract]   [Full Text] [Related]  

  • 42. Author Correction: SARS-CoV-2 disrupts host epigenetic regulation via histone mimicry.
    Kee J; Thudium S; Renner DM; Glastad K; Palozola K; Zhang Z; Li Y; Lan Y; Cesare J; Poleshko A; Kiseleva AA; Truitt R; Cardenas-Diaz FL; Zhang X; Xie X; Kotton DN; Alysandratos KD; Epstein JA; Shi PY; Yang W; Morrisey E; Garcia BA; Berger SL; Weiss SR; Korb E
    Nature; 2023 Feb; 614(7949):E44. PubMed ID: 36747034
    [No Abstract]   [Full Text] [Related]  

  • 43. Assessment of background levels of autoantibodies as a prognostic marker for severe SARS-CoV-2 infection.
    Sullivan FM; Tello A; Rauchhaus P; Santiago VH; Daly F
    J Circ Biomark; 2022; 11():24-27. PubMed ID: 35517714
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Molecular mimicry between SARS-CoV-2 spike glycoprotein and mammalian proteomes: implications for the vaccine.
    Kanduc D; Shoenfeld Y
    Immunol Res; 2020 Oct; 68(5):310-313. PubMed ID: 32946016
    [No Abstract]   [Full Text] [Related]  

  • 45. Human molecular chaperones share with SARS-CoV-2 antigenic epitopes potentially capable of eliciting autoimmunity against endothelial cells: possible role of molecular mimicry in COVID-19.
    Marino Gammazza A; Légaré S; Lo Bosco G; Fucarino A; Angileri F; Conway de Macario E; Macario AJ; Cappello F
    Cell Stress Chaperones; 2020 Sep; 25(5):737-741. PubMed ID: 32754823
    [TBL] [Abstract][Full Text] [Related]  

  • 46. SARS-CoV-2 and Guillain-Barré syndrome: molecular mimicry with human heat shock proteins as potential pathogenic mechanism.
    Lucchese G; Flöel A
    Cell Stress Chaperones; 2020 Sep; 25(5):731-735. PubMed ID: 32729001
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunoserologic Detection and Diagnostic Relevance of Cross-Reactive Autoantibodies in Coronavirus Disease 2019 Patients.
    Schiaffino MT; Di Natale M; García-Martínez E; Navarro J; Muñoz-Blanco JL; Demelo-Rodríguez P; Sánchez-Mateos P
    J Infect Dis; 2020 Oct; 222(9):1439-1443. PubMed ID: 32738141
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The SARS-CoV-2 as an instrumental trigger of autoimmunity.
    Dotan A; Muller S; Kanduc D; David P; Halpert G; Shoenfeld Y
    Autoimmun Rev; 2021 Apr; 20(4):102792. PubMed ID: 33610751
    [TBL] [Abstract][Full Text] [Related]  

  • 49. SARS-CoV-2 infection as a trigger of autoimmune response.
    Sacchi MC; Tamiazzo S; Stobbione P; Agatea L; De Gaspari P; Stecca A; Lauritano EC; Roveta A; Tozzoli R; Guaschino R; Bonometti R
    Clin Transl Sci; 2021 May; 14(3):898-907. PubMed ID: 33306235
    [TBL] [Abstract][Full Text] [Related]  

  • 50. COVID-19 and autoimmune diseases.
    Liu Y; Sawalha AH; Lu Q
    Curr Opin Rheumatol; 2021 Mar; 33(2):155-162. PubMed ID: 33332890
    [TBL] [Abstract][Full Text] [Related]  

  • 51. IgM autoantibodies recognizing ACE2 are associated with severe COVID-19.
    Casciola-Rosen L; Thiemann DR; Andrade F; Trejo Zambrano MI; Hooper JE; Leonard EK; Spangler JB; Cox AL; Machamer CE; Sauer L; Laeyendecker O; Garibaldi BT; Ray SC; Mecoli CA; Christopher-Stine L; Gutierrez-Alamillo L; Yang Q; Hines D; Clarke WA; Rothman R; Pekosz A; Fenstermacher KJ; Wang Z; Zeger SL; Rosen A
    medRxiv; 2020 Oct; ():. PubMed ID: 33083808
    [TBL] [Abstract][Full Text] [Related]  

  • 52. COVID-19 and Immunological Dysregulation: Can Autoantibodies be Useful?
    Pascolini S; Vannini A; Deleonardi G; Ciordinik M; Sensoli A; Carletti I; Veronesi L; Ricci C; Pronesti A; Mazzanti L; Grondona A; Silvestri T; Zanuso S; Mazzolini M; Lalanne C; Quarneti C; Fusconi M; Giostra F; Granito A; Muratori L; Lenzi M; Muratori P
    Clin Transl Sci; 2021 Mar; 14(2):502-508. PubMed ID: 32989903
    [TBL] [Abstract][Full Text] [Related]  

  • 53. SARS-CoV-2, the autoimmune virus.
    Halpert G; Shoenfeld Y
    Autoimmun Rev; 2020 Dec; 19(12):102695. PubMed ID: 33130000
    [No Abstract]   [Full Text] [Related]  

  • 54. Cross-reactions between rheumatoid factor and IgM SARS-CoV-2.
    Vinyé Bausà M; Bausà Peris R; Corominas H
    Med Clin (Barc); 2020 Nov; 155(9):417-418. PubMed ID: 32778426
    [No Abstract]   [Full Text] [Related]  

  • 55. Immune-mediated neurological syndromes in SARS-CoV-2-infected patients.
    Guilmot A; Maldonado Slootjes S; Sellimi A; Bronchain M; Hanseeuw B; Belkhir L; Yombi JC; De Greef J; Pothen L; Yildiz H; Duprez T; Fillée C; Anantharajah A; Capes A; Hantson P; Jacquerye P; Raymackers JM; London F; El Sankari S; Ivanoiu A; Maggi P; van Pesch V
    J Neurol; 2021 Mar; 268(3):751-757. PubMed ID: 32734353
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeting GM-CSF in COVID-19 Pneumonia: Rationale and Strategies.
    Bonaventura A; Vecchié A; Wang TS; Lee E; Cremer PC; Carey B; Rajendram P; Hudock KM; Korbee L; Van Tassell BW; Dagna L; Abbate A
    Front Immunol; 2020; 11():1625. PubMed ID: 32719685
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Autoimmune Encephalitis Concomitant with SARS-CoV-2 Infection: Insight from
    Grimaldi S; Lagarde S; Harlé JR; Boucraut J; Guedj E
    J Nucl Med; 2020 Dec; 61(12):1726-1729. PubMed ID: 32709734
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Diverse Functional Autoantibodies in Patients with COVID-19.
    Wang EY; Mao T; Klein J; Dai Y; Huck JD; Liu F; Zheng NS; Zhou T; Israelow B; Wong P; Lucas C; Silva J; Oh JE; Song E; Perotti ES; Fischer S; Campbell M; Fournier JB; Wyllie AL; Vogels CBF; Ott IM; Kalinich CC; Petrone ME; Watkins AE; ; Cruz CD; Farhadian SF; Schulz WL; Grubaugh ND; Ko AI; Iwasaki A; Ring AM
    medRxiv; 2021 Feb; ():. PubMed ID: 33330894
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome.
    Borghi MO; Beltagy A; Garrafa E; Curreli D; Cecchini G; Bodio C; Grossi C; Blengino S; Tincani A; Franceschini F; Andreoli L; Lazzaroni MG; Piantoni S; Masneri S; Crisafulli F; Brugnoni D; Muiesan ML; Salvetti M; Parati G; Torresani E; Mahler M; Heilbron F; Pregnolato F; Pengo M; Tedesco F; Pozzi N; Meroni PL
    Front Immunol; 2020; 11():584241. PubMed ID: 33178218
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Presence of antiphospholipid antibodies in COVID-19: a case series study.
    Amezcua-Guerra LM; Rojas-Velasco G; Brianza-Padilla M; Vázquez-Rangel A; Márquez-Velasco R; Baranda-Tovar F; Springall R; Gonzalez-Pacheco H; Juárez-Vicuña Y; Tavera-Alonso C; Sanchez-Muñoz F; Hernández-Salas M
    Ann Rheum Dis; 2021 May; 80(5):e73. PubMed ID: 32753426
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.